nach oben

Erschienen in:

2016 | OriginalPaper | Buchkapitel Zur Zeit gratis

1. Alternative Verfahren bei Prostatakrebs

verfasst von : Prof. Dr. med. M. Schostak, Prof. Dr. med. A. Blana, Priv.-Doz. Dr. med. R. Ganzer, Priv.-Doz. Dr. med. D. Baumunk, Dr. med. L. Sentker, Priv.-Doz. Dr. med. G. Salomon, Priv.-Doz. Dr. med. A. Roosen, Dr. med. F. Kahmann, Dr. med. T. O. Henkel

Erschienen in: Alternative operative Therapien in der Uroonkologie

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Im Spannungsfeld zwischen Ganzdrüsentherapien auf der einen Seite und Beobachten oder Nichtstun auf der anderen Seite suchen zahlreiche Betroffene mit Prostatakrebs nach sog. alternativen Behandlungen. Die am weitesten verbreitete Technik ist der hochintensive fokussierte Ultraschall (HIFU), dessen Verfahrensweise und Ergebnisse hier besonders ausführlich beschrieben werden. Das Konzept einer fokalen Therapie hat das Ziel, Tumorgewebe innerhalb der Prostata zu zerstören, unbetroffenes Gewebe im Organ jedoch zu schonen und dabei die Funktionen des Urogenitaltraktes möglichst zu erhalten. Als mögliche Therapieformen zur fokalen Therapie kommen HIFU, Brachytherapie, Kryotherapie, die irreversible Elektroporation und andere in Frage. Alle Verfahren werden bisher nur in Studien durchgeführt.

Blana A, Rogenhofer S, Ganzer R, Wild PJ, Wieland WF, Walter B (2006) Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer. World J Urol 24(5):585-590

Blana A, Murat FJ, Walter B, Thuroff S, Wieland WF, Chaussy C, Gelet A (2007) First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer. Eur Urol 53(6):1194-1201

Blana A, Hierl J, Rogenhofer S, Lunz JC, Wieland WF, Walter B, Bach T, Ganzer R (2008) Factors predicting for formation of bladder outlet obstruction after high-intensity focused ultrasound in treatment of localized prostate cancer. Urology 71(5):863–867

Blana A, Brown SC, Chaussy C, Conti GN, Eastham JA, Ganzer R, Murat FJ, Pasticier G, Rebillard X, Rewcastle JC, Robertson CN, Thuroff S, Ward JF (2009) High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU Int 104(8):1058-1062

Blana A, Robertson CN, Brown SC, Chaussy C, Crouzet S, Gelet A, Conti GN, Ganzer R, Pasticier G, Thuroff S, Ward JF (2012) Complete high-intensity focused ultrasound in prostate cancer: outcome from the @-Registry. Prostate Cancer Prostatic Dis 15(3):256-259

Chaussy C, Thüroff S (2003) The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep 4(3):248–252

Crouzet S, Rebillard X, Chevallier D, Rischmann P, Pasticier G, Garcia G, Rouvière O, Chapelon JY, Gelet A (2010) Multi-centric oncologic outcomes of high-intensity focused ultrasound for localized prostate cancer in 803 patients. Eur Urol 58(4):559–566PubMedCrossRef

Crouzet S, Chapelon JY, Rouviere O, Mege-Lechevallier F, Colombel M, Tonoli-Catez H, Martin X, Gelet A (2014) Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients. Eur Urol 65(5):907–914. doi: 10.1016/j.eururo.2013.04.039. Epub 2013 Apr 3PubMedCrossRef

D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH (2003) Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 21(11):2163–2172PubMedCrossRef

Ficarra V, Antoniolli SZ, Novara G, Parisi A, Fracalanza S, Martignoni G, Artibani W (2006) Short-term outcome after high-intensity focused ultrasound in the treatment of patients with high-risk prostate cancer. BJU Int 98(6):1193–1198PubMedCrossRef

Ganzer R, Fritsche HM, Brandtner A, Bründl J, Koch D, Wieland WF, Blana A (2013) Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer. BJU Int 112(3): 322–329. doi: 10.1111/j.1464-410X.2012.11715.x. Epub 2013 Jan 28PubMedCrossRef

Gelet A, Chapelon JY, Bouvier R, Rouvière O, Lasne Y, Lyonnet D, Dubernard JM (2000) Transrectal high-intensity focused ultrasound: minimally invasive therapy of localized prostate cancer. J Endourol 14(6):519–528PubMedCrossRef

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N, European Association of Urology (2014) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65(1):124 13–7. doi: 10.1016/j.eururo.2013.09.046. Epub 2013 Oct 6

Horwitz EM, Vicini FA, Ziaja EL, Dmuchowski CF, Stromberg JS, Martinez AA (1998) The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. American Society of Therapeutic Radiology and Oncology. Int J Radiat Oncol Biol Phys 41(2):267–272PubMedCrossRef

Huber P, Debus J, Jenne J, Jöchle K, van Kaick G, Lorenz WJ, Wannenmacher M (1996) Therapeutic ultrasound in tumor therapy. Principles, applications and new developments. Radiologe 36(1):64–71PubMedCrossRef

Illing RO, Leslie TA, Kennedy JE, Calleary JG, Ogden CW, Emberton M (2006) Visually directed high-intensity focused ultrasound for organ-confined prostate cancer: a proposed standard for the conduct of therapy. BJU Int 98(6):1187–1192PubMedCrossRef

Robert-Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (Hrsg) (2012) Krebs in Deutschland 2007/2008, 8. Ausgabe. RKI, Berlin 2012

Madersbacher S, Schatzl G, Djavan B, Stulnig T, Marberger M (2000) Long-term outcome of transrectal high-intensity focused ultrasound therapy for benign prostatic hyperplasia. Eur Urol 37(6):687–694PubMedCrossRef

Napoli A, Anzidei M, De Nunzio C, Cartocci G, Panebianco V, De Dominicis C, Catalano C, Petrucci F, Leonardo C (2013) Real-time magnetic resonance-guided high-intensity focused ultrasound focal therapy for localised prostate cancer: preliminary experience. Eur Urol 63(2):395–398PubMedCrossRef

Pinthus JH, Farrokhyar F, Hassouna MM, Woods E, Whelan K, Shayegan B, Orovan WL (2012) Single-session primary high-intensity focused ultrasonography treatment for localized prostate cancer: biochemical outcomes using third generation-based technology. BJU Int 110(8): 1142–1148. doi: 10.1111/j.1464-10X.2012.10945.x. Epub2012Feb 28PubMedCrossRef

Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65(4):965–974

Siddiqui K, Chopra R, Vedula S, Sugar L, Haider M, Boyes A, Musquera M, Bronskill M, Klotz L (2010) MRI-guided transurethral ultrasound therapy of the prostate gland using real-time thermal mapping: initial studies. Urology 76(6):1506–1511PubMedCrossRef

Simonin O, Savoie PH, Serment G, Bladou F, Karsenty G (2010) Urinary incontinence following open prostatectomy or laparoscopy for local prostate cancer: a review of relevant literature. Prog Urol 20(4):239–250PubMedCrossRef

Thüroff S (2003) The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep 4(3):248–252PubMedCrossRef

Thüroff S, Chaussy C (2013) Evolution and outcomes of 3 MHz high intensity focused ultrasound therapy for localized prostate cancer over 15 years. J Urol 190(2):702–710. doi: 10.1016/j.juro.2013.02.010. Epub 2013 Feb 13PubMedCrossRef

Uchida T, Shoji S, Nakano M, Hongo S, Nitta M, Murota A, Nagata Y (2009) Transrectal high-intensity focused ultrasound for the treatment of localized prostate cancer: eight-year experience. Int J Urol 16(11):881–886PubMedCrossRef

Vallancien G, Prapotnich D, Cathelineau X, Baumert H, Rozet F (2004) Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study. J Urol 171(6 Pt 1):2265–2267PubMedCrossRef

Walter B, Weiss T, Hofstädter F, Gaumann A, Hartmann A, Rogenhofer S, Ganzer R, Wach S, Engehausen D, Wieland WF, Blana A (2013) Utility of immunohistochemistry markers in the interpretation of post-high-intensive focussed ultrasound prostate biopsy cores. World J Urol 31(5):1129–1133PubMedCrossRef

Zelefsky MJ, Eastham JA, Cronin AM, Fuks Z, Zhang Z, Yamada Y, Vickers A, Scardino PT (2010) Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 28(9):1508–1513PubMedPubMedCentralCrossRef

Asimakopoulos AD, Miano R, Virgili G et al. (2012) HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study. Urol Oncol 30(5):577–583PubMedCrossRef

Berge V, Baco E, Karlsen SJ (2010) A prospective study of salvage high-intensity focused ultrasound for locally radiorecurrent prostate cancer: early results. Scand J Urol Nephrol 44(4):223–227PubMedCrossRef

Chalasani V, Martinez CH, Williams AK, Kwan K, Chin JL (2010) Histological changes in the human prostate after radio-therapy and salvage high intensity focused ultrasound. Can Urol Assoc J 4(4):E100–102CrossRef

Crouzet S, Murat FJ, Pommier P, Poissonnier L, Pasticier G, Rouviere O, Chapelon JY, Rabilloud M, Belot A, Mège-Lechevallier F, Tonoli-Catez H, Martin X, Gelet A (2012) Locally recurrent prostate cancer after initial radiation therapy: early salvage high-intensity focused ultrasound improves oncologic outcomes. Radiother Oncol 105(2):198–202PubMedCrossRef

El Fegoun AB, Barret E, Prapotnich D, Soon S, Cathelineau X, Rozet F, Galiano M, Sanchez-Salas R, Vallancien G (2011) Focal therapy with high-intensity focused ultrasound for prostate cancer in the elderly: a feasibility study with 10 years follow-up. Int Braz J Urol 37(2):213-219; discussion 220–222

Gelet A, Chapelon JY, Poissonnier L et al. (2004) Local recurrence of prostate cancer after external beam radio-therapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology 63(4):625–629PubMedCrossRef

Grimm P, Billiet I, Bostwick D et al. (2012) Comparative analysis of prostate-specific antigen free survival out-comes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 109(Suppl 1):22–29PubMedCrossRef

Grossmann M, Zajac JD (2011) Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated? Clin Endocrinol (Oxf) 74(3):289–293

Heidenreich A, Richter S, Thuer D, Pfister D (2010) Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. Eur Urol 57(3):437–443PubMedCrossRef

Ishiyama H, Hirayama T, Jhaveri P, Satoh T, Paulino AC, Xu B, Butler EB, Teh BS (2014) Is there an increase in genitourinary toxicity in patients treated with transurethral resection of the prostate and radiotherapy? A systematic review. Am J Clin Oncol 37(3):297–304PubMedCrossRef

Krol R, Hopman WP, Smeenk RJ, Van Lin EN (2012) Increased rectal wall stiffness after prostate radiotherapy: relation with fecal urgency. Neurogastroenterol Motil 24(4): 339-e166

Martino P, Scattoni V, Galosi AB, Consonni P, Trombetta C, Palazzo S, Maccagnano C, Liguori G, Valentino M, Battaglia M, Barozzi L (2011) Role of imaging and biopsy to assess local recurrence after definitive treatment for prostatecarcinoma (surgery, radiotherapy, cryotherapy, HIFU). World J Urol 29(5):595–605PubMedCrossRef

Meeks JJ, Brandes SB, Morey AF, Thom M, Mehdiratta N, Valadez C, Granieri MA, Gonzalez CM (2011) Urethroplasty for radiotherapy induced bulbomembranous strictures: a multi-institutional experience. J Urol 185(5):1761–1765. doi: 10.1016/j.juro.2010.12.038. Epub 2011 Mar 21PubMedCrossRef

Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO (2010) Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys 1;76(3 Suppl): S123–129CrossRef

Moliniè V, Mahjoub WK, Balaton A (2008) Histological modifications observed in prostate after preserving treatments for prostate cancer and their impact on Gleason score interpretation. Ann Pathol 28(5):363–373. doi: 10.1016/j. annpat.2008.07.008. Epub 2008 Oct 16PubMedCrossRef

Morris DE, Emami B, Mauch PM, Konski AA, Tao ML, Ng AK, Klein EA, Mohideen N, Hurwitz MD, Fraas BA, Roach M 3rd, Gore EM, Tepper JE (2005) Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative. Int J Radiat Oncol Biol Phys 62(1):3–19PubMedCrossRef

Murat FJ, Poissonnier L, Rabilloud M et al. (2009) Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur Urol 55(3):640–647PubMedCrossRef

Nguyen PL, D’Amico AV, Lee AK, Suh WW (2007) Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer 110(7):1417–1428PubMedCrossRef

Nilsson S, Norlén BJ, Widmark A (2004) A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol 43(4):316–381PubMedCrossRef

Olbert PJ, Heinis J, Hofmann R, Hegele A (2012) Choline PET/ CT in the diagnosis of primary and recurrent prostate cancer. Are there evidence-based indications? Urologe A 51(6):843–847. doi: 10.1007/s00120-012-2830-9PubMedCrossRef

Petraki CD, Sfikas CP (2007) Histopathological changes induced by therapies in the benign prostate and prostateadenocarcinoma. Histol Histopathol 22(1):107–118PubMed

Pinover WH, Horwitz EM, Hanlon AL, Uzzo RG, Hanks GE (2003) Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy. Cancer 97(4):1127–1233PubMedCrossRef

Poissonnier L, Murat FJ, Belot A et al. (2008) Locally recurrent prostatic adenocarcinoma after exclusive radiotherapy: results of high intensity focused ultrasound. Prog Urol 18(4):223–229PubMedCrossRef

Rajarubendra N, Bolton D, Lawrentschuk N (2010) Diagnosis of bone metastases in urological malignancies: an update. Urology 76(4):782–790PubMedCrossRef

Roznovanu SL, Radulescu D, Novac C, Stolnicu S (2005) The morphologic changes induced by hormone and radiation therapy on prostate carcinoma. Rev Med Chir Soc Med Nat lasi 109(2):337–342

Simonin O, Savoie PH, Serment G, Bladou F, Karsenty G (2010) Urinary incontinence following open prostatectomy or laparoscopy for local prostate cancer. A review of relevant literature. Prog Urol 20(4):239–250PubMedCrossRef

Sylvester J, Grimm P, Blasco J, Meier R, Spiegel J, Heaney C, Cavanagh W (2001) The role of androgen ablation in patients with biochemical or local failure after definitive radiation therapy: a survey of practice patterns of urologists and radiation oncologists in the United States. Urology 58(2 Suppl 1):65–70PubMedCrossRef

Welch HG, Albertsen PC (2009) Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 101(19):1325–1329PubMedPubMedCentralCrossRef

Wirth M, Fröhner M (2004) The significance of comorbidity and age in radical prostatectomy. Urologe A 43(8): 935–941PubMedCrossRef

Zacharakis E, Ahmed HU, Ishaq A et al. (2008) The feasibility and safety of high-intensity focused ultrasound as salvage therapy for recurrent prostate cancer following external beam radiotherapy. BJU Int 102(7):786–792PubMedCrossRef

Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, Amols H, Venkatraman ES, Leibel SA (2002) High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53(5):1111–1116PubMedCrossRef

Ahmed HU, Freeman A, Kirkham A, Sahu M, Scott R, Allen C, Van der Meulen J, Emberton M (2011) Focal therapy for localized prostate cancer: a phase I/II trial. J Urol 185(4): 1246–54. doi: 10.1016/j.juro.2010.11.079. Epub 2011 Feb 22PubMedCrossRef

Ahmed HU, Hindley RG, Dickinson L, Freeman A, Kirkham AP, Sahu M et al. (2012) Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol 13:622–632PubMedPubMedCentralCrossRef

Barret E, Ahallal Y, Sanchez-Salas R, Galiano M, Cosset JM, Validire P et al. (2013) Morbidity of focal therapy in the treatment of localized prostate cancer. Eur Urol 63:618–622PubMedCrossRef

van den Bos W, Muller, Crouzet S et al. (2014) Focal therapy in prostate cancer: international multidisciplinary consensus on trial design. Eur Urol 65:1078–1083PubMedCrossRef

Crouzet S, Rouviere O, Martin X, Gelet A (2014) High-intensity focused ultrasound as focal therapy of prostate cancer. Curr Opin Urol 24:225–230PubMedCrossRef

Ganzer R, Fritsche HM, Brandtner A, Brundl J, Koch D, Wieland WF et al. (2013) Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer. BJU Int 112:322–329PubMedCrossRef

Godtman RA, Holmberg E, Khatami A, Stranne J, Hugosson J (2013) Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Goteborg randomised population-based prostate cancer screening trial. Eur Urol 63:101–107PubMedCrossRef

Klotz L (2005) Active surveillance for prostate cancer: for whom? J Clin Oncol 23:8165–8169PubMedCrossRef

Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB et al. (2014) Overdiagnosis and overtreatment of prostate cancer. Eur Urol 65:1046–1055PubMedPubMedCentralCrossRef

McCormick KM (2002) A concept analysis of uncertainty in illness. J Nurs Scholarsh 34(2):127–131PubMedCrossRef

Meiers I, Waters DJ, Bostwick DG (2007) Preoperative prediction of multifocal prostate cancer and application of focal therapy: review 2007. Urology 70:3–8PubMedCrossRef

Muller B, van den Bos W, Brausi M, Cornud F, Gontero P, Kirkham A et al. (2013) The role of multiparametric magnetic resonance imaging in focal therapy for prostate cancer: a Delphi consensus project. 114(5):698–707. doi: 10.1111/bju.12548. Epub 2014 Aug 16

Muto S, Yoshii T, Saito K, Kamiyama Y, Ide H, Horie S (2008) Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer. Jpn J Clin Oncol 38:19219–9CrossRef

Penson DF (2009) Active surveillance: not your father's watchful waiting. Oncology 23:980, 98–2

de la Rosette J, Ahmed, Emberton M et al. (2010) Focal therapy in prostate cancerreport from a consensus panel. J Endourol 24:775–780CrossRef

Shoji S, Uchida T, Nakamoto M, Kim H, de Castro Abreu AL, Leslie S et al. (2013) Prostate swelling and shift during high intensity focused ultrasound: implication for targeted focal therapy. J Urol 190:1224–1232PubMedCrossRef

Van Velthoven R, Aoun F, Limani K, Narahari K, Lemort M, Peltier A (2014) Primary zonal high intensity focused ultrasound for prostate cancer: results of a prospective phase IIa feasibility study. Prostate Cancer 2014:756–189

Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S et al. (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367:203–213PubMedPubMedCentralCrossRef

Ahmed HU, Akin O, Coleman JA, Crane S, Emberton M, Goldenberg L, Hricak H, Kattan MW, Kurhanewicz J, Moore CM, Parker C, Polascik TJ, Scardino P, van As N, Villers A (2012) Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU Int 109(11):1636–1647PubMedCrossRef

Al Ekish S, Nayeemuddin M, Maddox M, Pareek G (2013) The role of cryosurgery of the prostate for nonsurgical candidates. JSLS 17(3):423–428. doi: 10.4293/108680813 X13693422518551PubMedPubMedCentralCrossRef

Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M (2002) Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 60(2 Suppl 1):3–11PubMedCrossRef

Bahn DK, Lee F, Silverman P, Bahn E, Badalament R, Kumar A, Greski J, Rewcastle JC (2003) Salvage cryosurgery for recurrent prostate cancer after radiation therapy: a seven-year follow-up. Clin Prostate Cancer 2(2):111–114PubMedCrossRef

Bahn DK, Silverman P, Lee F Sr., Badalament R, Bahn ED, Rewcastle JC (2006) Focal prostate cryoablation: initial results show cancer control and potency preservation. J Endourol 20(9):688-692. doi: 10.1089/end.2006.20.688PubMedCrossRef

Bahn D, de Castro Abreu AL, Gill IS, Hung AJ, Silverman P, Gross ME, Lieskovsky G, Ukimura O (2012) Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol 62(1):55–63. doi: 10.1016/j.eururo. 2012.03.006

Barret E, Ahallal Y, Sanchez-Salas R, Galiano M, Cosset JM, Validire P, Macek P, Durand M, Prapotnich D, Rozet F, Cathelineau X (2013) Morbidity of focal therapy in the treatment of localized prostate cancer. Eur Urol 63(4):618–622. doi: 10.1016/j.eururo.2012.11.057PubMedCrossRef

Baumunk D, Blana A, Ganzer R, Henkel T, Köllermann J, Roosen A, Machtens S, Salomon G, Sentker L, Witzsch U, Köhrmann KU, Schostak M, Arbeitsgruppe für Fokale und Mikrotherapie (2013) Focal prostate cancer therapy: capabilities, limitations and prospects. Urologe A 52(4):549–556PubMedCrossRef

Bozzini G, Colin P, Nevoux P, Villers A, Mordon S, Betrouni N (2013) Focal therapy of prostate cancer: energies and procedures. Urol Oncol 31(2):155–167. doi: 10.1016/j. urolonc.2012.05.011PubMedCrossRef

Campbell SC, Walsh PC (Hrsg) (2007) Urology. 9. Aufl, Bd 3. Saunders Elsevier, Philadelphia

D'Amico AV, Whittington R, Malkowicz SB, Schnall M, Tomaszewski J, Schultz D, Kao G, Van Arsdalen K, Wein A (1994) A multivariable analysis of clinical factors predicting for pathological features associated with local failure after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 30(2):293–302

Deutsche Gesellschaft für Urologie (2014) Interdisciplinary S3-guidelines on the early detection, diagnostics and therapy of the different stages of prostate cancer; AWMF registration number (034-022OL), Version 3.0

Eastham J (2015) A phase II study of focal cryoablation in low-risk prostate cancer. ClinicalTrials.gov database NCT00774436. https://clinicaltrials.gov/ct2/show/NCT00774436?term=NCT00774436&rank=1 . Zugegriffen: 23. März 2015

Ellis DS, Manny TB Jr, Rewcastle JC (2007) Focal cryosurgery followed by penile rehabilitation as primary treatment for localized prostate cancer: initial results. Urology 70(6 Suppl):9–15. doi: 10.1016/j.urology.2007.07.036PubMedCrossRef

Emberton M (2012) Tissue preservation may offer a harm-reduction strategy for men with early prostate cancer. Eur Urol 62(1):64-66; discussion 66–67. doi: 10.1016/ j.eururo.2012.03.043CrossRef

Guazzoni G (2015) Focal therapy for organ defined prostate cancer: an investigative prospective pilot study. Clinical-Trials.gov database NCT00928603. https://clinicaltrials.gov/ct2/show/NCT00928603?term=N-CT00928603&rank=1 . Zugegriffen: 23. März 2015

Han KR, Cohen JK, Miller RJ, Pantuck AJ, Freitas DG, Cuevas CA, Kim HL, Lugg J, Childs SJ, Shuman B, Jayson MA, Shore ND, Moore Y, Zisman A, Lee JY, Ugarte R, Mynderse LA, Wilson TM, Sweat SD, Zincke H, Belldegrun AS (2003) Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol 170(4 Pt 1):1126–1130. doi: 10.1097/01. ju.0000087860.52991.a8PubMedCrossRef

Hoffmann NE, Bischof JC (2002) The cryobiology of cryosurgical injury. Urology 60(2 Suppl 1):40-49PubMedCrossRef

Kasivisvanathan V, Emberton M, Ahmed HU (2013) Focal therapy for prostate cancer: rationale and treatment opportunities. Clin Oncol (R Coll Radiol) 25(8):461–473. doi: 10.1016/j.clon.2013.05.002

Lambert EH, Bolte K, Masson P, Katz AE (2007) Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. Urology 69(6):1117–1120. doi: 10.1016/j.urology.2007.02.047PubMedCrossRef

Long JP, Bahn D, Lee F, Shinohara K, Chinn DO, Macaluso JN Jr (2001) Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology 57(3):518–523PubMedCrossRef

Nguyen HD, Allen BJ, Pow-Sang JM (2013) Focal cryotherapy in the treatment of localized prostate cancer. Cancer Control 20(3):177–180PubMed

Onik G, Narayan P, Vaughan D, Dineen M, Brunelle R (2002) Focal »nerve-sparing« cryosurgery for treatment of primary prostate cancer: a new approach to preserving potency. Urology 60(1):109–114PubMedCrossRef

Onik G, Vaughan D, Lotenfoe R, Dineen M, Brady J (2007) »Male lumpectomy«: focal therapy for prostate cancer using cryoablation. Urology 70(6 Suppl):16–21. doi: 10.1016/j.urology.2007.06.001PubMedCrossRef

Onik G, Vaughan D, Lotenfoe R, Dineen M, Brady J (2008) The »male lumpectomy«: focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. Urol Oncol 26(5):500–505. doi: 10.1016/j.urolonc.2008.03.004PubMedCrossRef

Pisters LL, von Eschenbach AC, Scott SM, Swanson DA, Dinney CP, Pettaway CA, Babaian RJ (1997) The efficacy and complications of salvage cryotherapy of the prostate. J Urol 157(3):921–925PubMedCrossRef

Shinohara K, Rhee B, Presti JC Jr, Carroll PR (1997) Cryosurgical ablation of prostate cancer: patterns of cancer recurrence. J Urol 158(6):2206-2209; discussion 2209–2210CrossRef

Truesdale MD, Cheetham PJ, Hruby GW, Wenske S, Conforto AK, Cooper AB, Katz AE (2010) An evaluation of patient selection criteria on predicting progression-free survival after primary focal unilateral nerve-sparing cryoablation for prostate cancer: recommendations for follow up. Cancer J 16(5):544–549PubMedCrossRef

Ukimura O, de Castro Abreu AL, Gill IS, Shoji S, Hung AJ, Bahn D (2013) Image visibility of cancer to enhance targeting precision and spatial mapping biopsy for focal therapy of prostate cancer. BJU Int 111(8):E354–364. doi: 10.1111/ bju.12124CrossRef

Valerio M, Ahmed HU, Emberton M, Lawrentschuk N, Lazzeri M, Montironi R, Nguyen PL, Trachtenberg J, Polascik TJ (2014) The role of focal therapy in the management of localised prostate cancer: a systematic review. Eur Urol 66(4): 732–751. doi: 10.1016/j.eururo.2013.05.048PubMedPubMedCentralCrossRef

Ward JF, Jones JS (2012) Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry. BJU Int 109(11):1648–1654. doi: 10.1111/j.1464-410X.2011.10578.xPubMedCrossRef

Ward JF (2015) Regional cryoablation for localized adenocarcinoma of the prostate. ClinicalTrials.gov database NCT00877682. https://clinicaltrials.gov/ct2/show/NCT00877682?term=NCT00877682&rank=1 . Zugegriffen: 23. März 2015

Ahmed HU, Akin O, Coleman JA, Crane S, Emberton M, Goldenberg L, Hricak H, Kattan MW, Kurhanewicz J, Moore CM, Parker C, Polascik TJ, Scardino P, van As N, Villers A, Transatlantic Consensus Group on Active Surveillance and Focal Therapy for Prostate Cancer (2012) Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer BJU Int 109(11):1636–1647PubMedCrossRef

Azzouzi AR, Barret E, Moore CM, Villers A, Allen C, Scherz A, Muir G, de Wildt M, Barber NJ, Lebdai S, Emberton M (2013) TOOKAD Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer. BJU Int 112(6):766–774PubMedCrossRef

Betrouni N et al. (2011) A model to estimate the outcome of prostate cancer photodynamic therapy with TOOKAD Soluble WST-11. Phys Med Biol 56:4771-4783

Moore CM, Emberton M, Bown SG (2011) Photodynamic therapy for prostate cancer–an emerging approach for organ-confined disease. Lasers Surg Med 43:76–8

Nathan TR et al. (2002) Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study. J Urol 168:1427–1432PubMedCrossRef

Patel H et al. (2008) Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen. Clin Cancer Res 14:4869-4876

Trachtenberg J et al. (2007) Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response. J Urol 178:1974–1979

Trachtenberg J et al. (2008) Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int 102:556–562PubMedCrossRef

Von Tappeiner H, Jodlbauer A (Hrsg) Die sensibilisierende Wirkung fluorescierender Substanzen. Gesammelte Untersuchung über die photodynamische Untersuchung. FCW Vogel, Leipzig 1907

Weersink RA et al. (2005) Techniques for delivery and monitoring of TOOKAD (WST09)-mediated photodynamic therapy of the prostate: clinical experience and practicalities J Photochem Photobiol B79:211–222

Windahl T et al. (1990) Photodynamic therapy of localised prostatic cancer. Lancet 336:1139

Zaak D et al. (2003) Photodynamic therapy by means of 5-ALA induced PPIX in human prostate cancer: preliminary results. Med Laser Appl 18:91–95

Aaltomaa SH, Kataja VV, Lahtinen T et al. (2009) Eight years experience of local prostate cancer treatment with permanent I125 seed brachytherapy-morbidity and outcome results. Radiother Oncol 91:213–216PubMedCrossRef

Bowes D, Crook J (2011) A critical analysis of the long-term impact of brachytherapy for prostate cancer: a review of the recent literature. Curr Opin Urol 21:219–224PubMedCrossRef

Crook J, Borg J, Evans A et al. (2011) 10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: results for 1.100 patients. Int J Radiat Oncol Biol Phys 80:1323–1329PubMedCrossRef

Franca CA, Vieira SL, Carvalho AC et al. (2009) Radioactive seed migration after prostate brachytherapy with iodine-125 using loose seeds versus stranded seeds. Int Braz J Urol 35:573-579; discussion 579–580CrossRef

Grimm P, Billiet I, Bostwick D et al. (2012) Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 109(Suppl 1):22–29PubMedCrossRef

Hathout L, Donath D, Moumdjian C et al. (2011) Analysis of seed loss and pulmonary seed migration in patients treated with virtual needle guidance and robotic seed delivery. Am J Clin Oncol 34:449–453PubMedCrossRef

Hau EK, Oborn BM, Bucci J (2011) An unusual case of radioactive seed migration to the vertebral venous plexus and renal artery with nerve root compromise. Brachytherapy 10:295–298PubMedCrossRef

Heidenreich A, Bellmunt J, Bolla M et al. (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61–71PubMedCrossRef

Henry AM, Al-Qaisieh B, Gould K et al. (2010) Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experience. Int J Radiat Oncol Biol Phys 76:50–56PubMedCrossRef

Herbert C, Morris WJ, Hamm J et al. (2011) The effect of loose versus stranded seeds on biochemical no evidence of disease in patients with carcinoma of the prostate treated with iodine-125 brachytherapy. Brachytherapy 10:442–448PubMedCrossRef

Hinnen KA, Battermann JJ, van Roermund JG et al. (2010a) Long-term biochemical and survival outcome of 921 patients treated with I-125 permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 76:1433–1438PubMedCrossRef

Hinnen KA, Moerland MA, Battermann JJ et al. (2010b) Loose seeds versus stranded seeds in I-125 prostate brachytherapy: differences in clinical outcome. Radiother Oncol 96:30–33PubMedCrossRef

Keyes M, Miller S, Moravan V et al. (2009) Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys 73:1023–1032PubMedCrossRef

Keyes M, Spadinger I, Liu M et al. (2012) Rectal toxicity and rectal dosimetry in low-dose-rate (125)I permanent prostate implants: a long-term study in 1.006 patients. Brachytherapy 11:199–208PubMedCrossRef

Knaup C, Mavroidis P, Esquivel C et al. (2012) Investigating the dosimetric and tumor control consequences of prostate seed loss and migration. Med Phys 39:3291–3298PubMedPubMedCentralCrossRef

Martin T, Wenz F, Bohmer D et al. (2010) Radiation therapy for prostate cancer in the new S3 guideline. Part 2: postoperative radiation therapy and brachytherapy. Urologe A 49:216–220PubMedCrossRef

Munro NP, Al-Qaisieh B, Bownes P et al. (2010) Outcomes from Gleason 7, intermediate risk, localized prostate cancer treated with Iodine-125 monotherapy over 10 years. Radiother Oncol 96:34–37PubMedCrossRef

Nguyen BD, Egnatios GL (2010) Prostate brachytherapy seed migration to the left testicular vein. Brachytherapy 9:224–226PubMedCrossRef

Nguyen BD, Schild SE, Wong WW et al. (2009) Prostate brachytherapy seed embolization to the right renal artery. Brachytherapy 8:309–312PubMedCrossRef

Polo A, Salembier C, Venselaar J et al. (2010) Review of intraoperative imaging and planning techniques in permanent seed prostate brachytherapy. Radiother Oncol 94:12–23PubMedCrossRef

Prada PJ, Juan G, Gonzalez-Suarez H et al. (2010) Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent iodine implants. BJU Int 106:32–36PubMedCrossRef

Robert-Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (Hrsg) (2012) Krebs in Deutschland 2007/2008, 8. Ausgabe. RKI, Berlin 2012

Rosenthal SA, Bittner NH, Beyer DC et al. (2011) American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 79:335–341PubMedCrossRef

Rosser CJ, Chichakli R, Levy LB et al. (2002) Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with external beam radiation. J Urol 168:536–541PubMedCrossRef

Shapiro EY, Rais-Bahrami S, Morgenstern C et al. (2009) Long-term outcomes in younger men following permanent prostate brachytherapy. J Urol 181:1665-1671; discussion 1671PubMedCrossRef

Snyder KM, Stock RG, Buckstein M et al. (2012) Long-term potency preservation following brachytherapy for prostate cancer. BJU Int 110:221–225PubMedCrossRef

Sugawara A, Nakashima J, Shigematsu N et al. (2009) Prediction of seed migration after transperineal interstitial prostate brachytherapy with I-125 free seeds. Brachytherapy 8:52–56PubMedCrossRef

Sugawara A, Nakashima J, Kunieda E et al. (2011) Incidence of seed migration to the chest, abdomen, and pelvis after transperineal interstitial prostate brachytherapy with loose (125)I seeds. Radiat Oncol 6:13–0CrossRef

Sugawara A, Nakashima J, Kunieda E et al. (2012) Prostate brachytherapy seed migration to a left varicocele. Brachytherapy 11:502–506PubMedCrossRef

Sylvester JE, Grimm PD, Wong J et al. (2011) Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience. Int J Radiat Oncol Biol Phys 81:376–381PubMedCrossRef

Taira AV, Merrick GS, Butler WM et al. (2011) Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 79:1336–1342PubMedCrossRef

Thompson I, Thrasher JB, Aus G et al. (2007) Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177:2106–2131PubMedCrossRef

Whaley JT, Levy LB, Swanson DA et al. (2012) Sexual function and the use of medical devices or drugs to optimize potency after prostate brachytherapy. Int J Radiat Oncol Biol Phys 82:e765–771CrossRef

Zelefsky MJ, Kuban DA, Levy LB et al. (2007) Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 67:327–333PubMedCrossRef

Ahmed HU (2009) The index lesion and the origin of prostate cancer. N Engl J Med 361:1704–1706PubMedCrossRef

Ahmed HU, Akin O, Coleman JA, Crane S, Emberton M, Goldenberg L, Hricak H, Kattan MW, Kurhanewicz J, Moore CM, Parker C, Polascik TJ, Scardino P, Van As N, Villers A (2012) Transatlantic Consensus Group on active surveillance and focal therapy für prostate cancer. BJU Int 109(11):1636–1647. doi: 10.1111/j.1464-410X.2011. 10633.x. Epub 2011 Nov 11PubMedCrossRef

Bott SR, Ahmed HU, Hindley RG, Abdul-Rahman A, Freeman A, Emberton M (2010) The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer. BJU Int 106(11):1607–1611PubMedCrossRef

Cool DW, Zhang X, Romagnoli C, Izawa JI, Romano WM, Fenster A (2015) Evaluation of MRI-TRUS fusion versus cognitive registration accuracy for MRI-targeted, TRUS-guided prostate biopsy. AJR Am J Roentgenol 204(1):83–91PubMedCrossRef

Cosset JM, Wakil G, Pierrat N, Cathelineau X, Marchand V, Vallancien G (2011) Poster 710. Focal brachytherapy for prostate cancer: a pilot study. Radiotherapy and Oncology 99:S28–3

Cosset JM, Cathelineau X, Wakil G, Pierraat N, Quenzer O, Prapotnich D, Barret E, Rozet F, Galiano M, Vallancien, G (2013) Focal brachytherapy for selected low risk prostate cancers: a pilot study. Brachytherapy 12:331–337PubMedCrossRef

Huo AS et al. (2012) Accuracy of primary systematic template guided transperineal biopsy of the prostate for locating prostate cancer: a comparison with radical prostatectomy specimens. J Urol 187:2044–2049PubMedCrossRef

Kasivisvanathan V, Emberton M, Ahmed HU (2013) Focal therapy for prostate cancer: rationale and treatment oppurtunities. J Clin Oncol 25:461-473

Kasivisvanathan V, Shah TT, Donaldson I, Kanthabalan A, Moore CM, Emberton M, Ahmed HU (2015) Fokale Therapie des Prostatakarzinoms. Urologe 54:202–209

Langley S, Ahmed HU, Al-Qaisieh B, Bostwick D, Dickinson L, GomezVeiga F, Grimm P, Machtens S, Guedea F, Emberton M (2012) Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer. BJU Int 109(Suppl 1):7–16PubMedCrossRef

Losa A et al. (2013) Complications and quality of life after template-assisted transperineal prostate biopsy in patients eligible for focal therapy. Urology 81:1291–1296PubMedCrossRef

Masterson TA, Cheng L, Mehan RM, Koch MO (2011) Tumor focality does not predict biochemical recurrence after radical prostatectomy in men with clinically localized prostate cancer. J Urol 186(2):506–510PubMedCrossRef

Morris WJ et al. (2013) British Columbia Cancer Agency. FTPC (Focal Therapy for Prostate Cancer): a pilot study using focal low dose rate brachytherapy as an alternative to active surveillance and radical treatment for favourable risk prostate cancer. ClinicalTrials.gov database NCT01830166 [updated September 8, 2014]. https://clinicaltrials.gov/ct2/show/NCT01830166 . Zugegriffen: 24. Mai 2015

Roethke M, Blondin D, Schlemmer HP, Franiel T (2013) PI-RADS Klassifikation: Struktuiertes Befundungsschema für die MRT der Prostata. Rofo 185:253–261CrossRef

Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, Okoro C, Raskolnikov D, Parnes HL, Linehan WM, Merino MJ, Simon RM, Choyke PL, Wood BJ, Pinto PA (2015) Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA 313(4):390–397PubMedPubMedCentralCrossRef

Taira AV et al. (2010) Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. Prostate Cancer Prostatic Dis 13:71–77PubMedCrossRef

Turkbey B et al. (2012) Correlation of magnetic resonance imaging tumor volume with histopathology. J Urol 188:1157–1163PubMedCrossRef

Zelefsky M et al. (2011) Memorial Sloan-Kettering Cancer Center. Phase II study assessing the potential for reduced toxicity using focal brachytherapy early stage, low volume in prostate cancer. ClinicalTrials.gov database NCT01354951 [updated May 13, 2013]. https://clinicaltrials.gov/ct2/show/NCT01354951 . Zugegriffen: 24. Mai 2015

Titel: Alternative Verfahren bei Prostatakrebs
verfasst von: Prof. Dr. med. M. Schostak
Prof. Dr. med. A. Blana
Priv.-Doz. Dr. med. R. Ganzer
Priv.-Doz. Dr. med. D. Baumunk
Dr. med. L. Sentker
Priv.-Doz. Dr. med. G. Salomon
Priv.-Doz. Dr. med. A. Roosen
Dr. med. F. Kahmann
Dr. med. T. O. Henkel
Verlag: Springer Berlin Heidelberg
Buch: Alternative operative Therapien in der Uroonkologie
Print ISBN: 978-3-662-44419-1

Electronic ISBN: 978-3-662-44420-7

Copyright-Jahr: 2016
DOI: https://doi.org/10.1007/978-3-662-44420-7_1

Neu im Fachgebiet Urologie

25.04.2024 | Nierenkarzinom | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

1. Alternative Verfahren bei Prostatakrebs

Zusammenfassung

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie